Eucapnic intermittent hypoxia augments endothelin-1 vasoconstriction in rats: role of PKCdelta

Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H920-7. doi: 10.1152/ajpheart.01264.2007. Epub 2007 Dec 14.

Abstract

We reported previously that simulating sleep apnea by exposing rats to eucapnic intermittent hypoxia (E-IH) causes endothelin-dependent hypertension and increases constrictor sensitivity to endothelin-1 (ET-1). In addition, augmented ET-1-induced constriction in small mesenteric arteries (sMA) is mediated by increased Ca(2+) sensitization independent of Rho-associated kinase. We hypothesized that exposing rats to E-IH augments ET-1-mediated vasoconstriction by increasing protein kinase C (PKC)-dependent Ca(2+) sensitization. In sMA, the nonselective PKC inhibitor GF-109203x (3 microM) significantly inhibited ET-1-stimulated constriction in E-IH arteries but did not affect ET-1-stimulated constriction in sham arteries. Phospholipase C inhibitor U-73122 (1 microM) also inhibited constriction by ET-1 in E-IH but not sham sMA. In contrast, the classical PKC (cPKC) inhibitor Gö-6976 (1 microM) had no effect on ET-1-mediated vasoconstriction in either group, but a PKCdelta-selective inhibitor (rottlerin, 3 microM) significantly decreased ET-1-mediated constriction in E-IH but not in sham sMA. ET-1 increased PKCdelta phosphorylation in E-IH but not sham sMA. In contrast, ET-1 constriction in thoracic aorta from both sham and E-IH rats was inhibited by Gö-6976 but not by rottlerin. These observations support our hypothesis that E-IH exposure significantly increases ET-1-mediated constriction of sMA through PKCdelta activation and modestly augments ET-1 contraction in thoracic aorta through activation of one or more cPKC isoforms. Therefore, upregulation of a PKC pathway may contribute to elevated ET-1-dependent vascular resistance in this model of hypertension.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / physiology
  • Blood Pressure / drug effects
  • Body Weight / drug effects
  • Carbon Dioxide / physiology*
  • Diglycerides / metabolism
  • Endothelin-1 / pharmacology*
  • Endothelium, Vascular / drug effects
  • Enzyme Inhibitors / pharmacology
  • Hypoxia / physiopathology*
  • In Vitro Techniques
  • Male
  • Mesenteric Arteries / physiology
  • Muscle Contraction / drug effects
  • Muscle, Smooth, Vascular / drug effects
  • Protein Kinase C-delta / antagonists & inhibitors
  • Protein Kinase C-delta / physiology*
  • Rats
  • Rats, Sprague-Dawley
  • Type C Phospholipases / antagonists & inhibitors
  • Vasoconstriction / drug effects*
  • Vasoconstriction / physiology

Substances

  • Diglycerides
  • Endothelin-1
  • Enzyme Inhibitors
  • Carbon Dioxide
  • Protein Kinase C-delta
  • Type C Phospholipases